Question 1

What is the ESG rating for ABBV?

Accepted Answer

AbbVie Inc. has the following ESG ratings: MSCI ESG Rating: BBB, Sustainalytics ESG Risk: 25, ESG Enterprise Score: 60.

Question 2

What are the main strengths of investing in ABBV?

Accepted Answer

The main strengths of investing in AbbVie Inc. include: Life-changing treatments for autoimmune and other diseases, 25% carbon emission reduction goal with renewable energy adoption, Strong compliance programs critical for pharma industry.

Question 3

What are the potential drawbacks of investing in ABBV?

Accepted Answer

Potential drawbacks of investing in AbbVie Inc. include: Aggressive Humira pricing and patent strategies drew major criticism, Drug affordability remains key social responsibility challenge, Limited transparency on pricing decisions and access programs.

Question 4

What are the key financial metrics for ABBV?

Accepted Answer

Key financial metrics for AbbVie Inc. include: Market Cap: $1.12 billion, Current Price: $40.19, Dividend Yield: 3.54%.

AbbVie Inc.

Detailed View

ABBV

ESG Ratings